At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLYS Mineralys Therapeutics, Inc.
Pre-Mkt 03-18 05:29:42 EDT
25.02
-0.71
-2.76%
盘前24.86
-0.16-0.64%
05:09 EDT
High25.86Low24.90Vol1.07M
Open25.65D1 Closing25.73Amplitude3.73%
Mkt Cap2.06BTradable Cap1.52BTotal Shares82.40M
T/O27.00MT/O Rate1.77%Tradable Shares60.57M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Mineralys CMO David Malcom Rodman disposes of USD 557,000 in common shares
Reuters  ·  03-17 05:20
Mineralys CMO David Malcom Rodman disposes of USD 557,000 in common shares
BRIEF-Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Reuters  ·  03-17 05:05
BRIEF-Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Mineralys Therapeutics grants inducement equity awards covering 48,860 shares under 2025 plan
Reuters  ·  03-17 04:09
Mineralys Therapeutics grants inducement equity awards covering 48,860 shares under 2025 plan
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Aprea Therapeutics (APRE)
TIPRANKS  ·  03-17 00:40
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Aprea Therapeutics (APRE)
Mineralys Therapeutics, Inc. (MLYS) Receives a Buy from Wells Fargo
TIPRANKS  ·  03-15
Mineralys Therapeutics, Inc. (MLYS) Receives a Buy from Wells Fargo
Stock Track | Mineralys Therapeutics Soars 5.26% Intraday on Bank of America's Buy Rating Reiteration
Stock Track  ·  03-13
Stock Track | Mineralys Therapeutics Soars 5.26% Intraday on Bank of America's Buy Rating Reiteration
Bank of America Securities Sticks to Their Buy Rating for Mineralys Therapeutics, Inc. (MLYS)
TIPRANKS  ·  03-13
Bank of America Securities Sticks to Their Buy Rating for Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics Q4 Loss Narrows
MT Newswires Live  ·  03-13
Mineralys Therapeutics Q4 Loss Narrows
Earnings Flash (MLYS) Mineralys Therapeutics Posts Q4 Loss of $0.40, vs. FactSet Est of $0.52 Loss
MT Newswires Live  ·  03-13
Earnings Flash (MLYS) Mineralys Therapeutics Posts Q4 Loss of $0.40, vs. FactSet Est of $0.52 Loss
Mineralys Therapeutics Inc expected to post a loss of 53 cents a share - Earnings Preview
Reuters  ·  03-11
Mineralys Therapeutics Inc expected to post a loss of 53 cents a share - Earnings Preview
Mineralys Therapeutics' Treatment Fails to Reduce Sleep Apnea
Dow Jones  ·  03-10
Mineralys Therapeutics' Treatment Fails to Reduce Sleep Apnea
FDA accepts Mineralys Therapeutics’ lorundrostat NDA with Dec. 22, 2026 PDUFA date
Reuters  ·  03-10
FDA accepts Mineralys Therapeutics’ lorundrostat NDA with Dec. 22, 2026 PDUFA date
Mineralys Therapeutics Inc - FDA Assigns Pdufa Target Action Date of December 22, 2026 for Lorundrostat Nda
THOMSON REUTERS  ·  03-10
Mineralys Therapeutics Inc - FDA Assigns Pdufa Target Action Date of December 22, 2026 for Lorundrostat Nda
Mineralys Therapeutics Announces FDA Acceptance of Nda for Lorundrostat for Treatment of Adults With Hypertension and Topline Explore-Osa Trial Results
THOMSON REUTERS  ·  03-10
Mineralys Therapeutics Announces FDA Acceptance of Nda for Lorundrostat for Treatment of Adults With Hypertension and Topline Explore-Osa Trial Results
Mineralys Therapeutics Files Initial Beneficial Ownership Statement for Chief Commercial Officer Eric Warren
Reuters  ·  03-05
Mineralys Therapeutics Files Initial Beneficial Ownership Statement for Chief Commercial Officer Eric Warren
A Look At Mineralys Therapeutics (MLYS) Valuation As Lorundrostat Progress Shapes Investor Optimism
Simply Wall St.  ·  03-02
A Look At Mineralys Therapeutics (MLYS) Valuation As Lorundrostat Progress Shapes Investor Optimism
Mineralys Therapeutics Reports Inducement Equity Awards Under Nasdaq Rule 5635(c)(4)
Reuters  ·  02-27
Mineralys Therapeutics Reports Inducement Equity Awards Under Nasdaq Rule 5635(c)(4)
Mineralys Therapeutics Chief Medical Officer David Malcom Rodman Reports Common Share Disposal
Reuters  ·  02-18
Mineralys Therapeutics Chief Medical Officer David Malcom Rodman Reports Common Share Disposal
Mineralys Therapeutics Grants Inducement Equity Awards to New Employees
Reuters  ·  02-12
Mineralys Therapeutics Grants Inducement Equity Awards to New Employees
Press Release: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Dow Jones  ·  02-12
Press Release: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Introduction

Company Name.
Mineralys Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Issue price:
--